Niraparib alone or with bevacizumab for advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult woman (age 18 or older) with a specific type of ovarian, fallopian tube, or peritoneal cancer that is advanced and high grade
- You already had debulking surgery for this cancer, or you are planning to start chemotherapy first with surgery in the middle (interval debulking)
- You can start study treatment within 8 weeks after your cancer surgery
- Your tumor tissue is available to test for BRCA status at a central lab before randomization
- Recent blood tests are good enough (enough white blood cells, platelets, and hemoglobin) and liver/kidney tests meet limits
- Your general health is strong enough (good activity level), and you can follow frequent study visits and questionnaires
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of two targeted drugs, niraparib and abemaciclib, for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back after at least two prior chemotherapies. It may be an option if you have no standard treatments left and your cancer still responds to platinum-based chemotherapy.
This trial tests whether adding niraparib (a pill treatment that targets cancer cell DNA repair) after surgery can help people with ovarian cancer that has come back. It focuses on “platinum-sensitive” cases and tries to remove all visible tumor when possible.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.